October 23, 2015 8:16 AM | 1 min read |
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced that it would provide a meaningful update on its CD20 Chimeric Antigen Receptor T-cell (CAR-T) Phase IIa trial in Advanced, Refractory or Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) at the upcoming 4th International Conference on Translational Medicine to be held on October 26-28, 2015 in Baltimore, Maryland, USA.Title: Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory B-cell Non-Hodgkin's lymphoma: An early Phase IIa trial reportScientific Program: October 26, 2015 16:15-16:40 EDTLocation: DoubleTree by Hilton Hotel Baltimore - BWI Airport, Chesapeake HallPresenter: Yihong Yao, Ph.D., Chief Scientific Officer, Cellular Biomedicine GroupFull details of the presented data will be available on the Company's website following the presentation.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.